BIOLASE INC (BIOL)
US0909117022 - Common Stock
We assign a fundamental rating of 1 out of 10 to BIOL. BIOL was compared to 195 industry peers in the Health Care Equipment & Supplies industry. BIOL has a bad profitability rating. Also its financial health evaluation is rather negative. BIOL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BIOL has reported negative net income.
BIOL had a negative operating cash flow in the past year.
In the past 5 years BIOL always reported negative net income.
In the past 5 years BIOL always reported negative operating cash flow.
1.2 Ratios
BIOL has a Return On Assets of -107.18%. This is amonst the worse of the industry: BIOL underperforms 83.59% of its industry peers.
Looking at the Return On Equity, with a value of -1923.47%, BIOL is doing worse than 89.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.18% | ||
| ROE | -1923.47% | ||
| ROIC | N/A |
ROA(3y)-70.98%
ROA(5y)-70.48%
ROE(3y)-859.83%
ROE(5y)-666.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BIOL has a worse Gross Margin (34.03%) than 68.72% of its industry peers.
BIOL's Gross Margin has been stable in the last couple of years.
BIOL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.03% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.89%
GM growth 5Y-1.46%
2. Health
2.1 Basic Checks
BIOL does not have a ROIC to compare to the WACC, probably because it is not profitable.
BIOL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BIOL has more shares outstanding
BIOL has a worse debt/assets ratio than last year.
2.2 Solvency
BIOL has an Altman-Z score of -12.66. This is a bad value and indicates that BIOL is not financially healthy and even has some risk of bankruptcy.
BIOL has a Altman-Z score of -12.66. This is amonst the worse of the industry: BIOL underperforms 80.51% of its industry peers.
A Debt/Equity ratio of 6.02 is on the high side and indicates that BIOL has dependencies on debt financing.
The Debt to Equity ratio of BIOL (6.02) is worse than 90.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 6.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.66 |
ROIC/WACCN/A
WACC12.28%
2.3 Liquidity
BIOL has a Current Ratio of 1.26. This is a normal value and indicates that BIOL is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BIOL (1.26) is worse than 89.23% of its industry peers.
BIOL has a Quick Ratio of 1.26. This is a bad value and indicates that BIOL is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.68, BIOL is not doing good in the industry: 93.85% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.68 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 92.22% over the past year.
BIOL shows a small growth in Revenue. In the last year, the Revenue has grown by 1.44%.
The Revenue has been growing slightly by 1.27% on average over the past years.
EPS 1Y (TTM)92.22%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q98.63%
Revenue 1Y (TTM)1.44%
Revenue growth 3Y29.23%
Revenue growth 5Y1.27%
Revenue growth Q2Q-3.99%
3.2 Future
The Earnings Per Share is expected to grow by 41.30% on average over the next years. This is a very strong growth
BIOL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.20% yearly.
EPS Next Y98.98%
EPS Next 2Y41.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.66%
Revenue Next 2Y6.2%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BIOL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIOL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BIOL's earnings are expected to grow with 41.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.3%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BIOL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOLASE INC
NASDAQ:BIOL (4/26/2024, 7:00:00 PM)
After market: 0.148 0 (0%)0.148
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.81M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.18% | ||
| ROE | -1923.47% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.03% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 6.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.68 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)92.22%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y98.98%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.44%
Revenue growth 3Y29.23%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y